NEW YORK (Reuters) - GlaxoSmithKline and its partner Adolor Corp.said on Monday their drug to treat gastrointestinal side effects of opioid painkillers was linked to higher risk of heart attacks and other serious heart problems, fractures and skin cancers in a late-stage trial.
The drugmakers said the negative findings came from a year-long Phase III study of their experimental drug, alvimopan, involving 805 patients experiencing bowel dysfunction as a result of taking opioids for treatment of chronic non-cancer pain.
http://www.reuters.com/article/healthNews/idUSWEN624820070409?feedType=RSS
No comments:
Post a Comment